Status:
COMPLETED
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
Lead Sponsor:
Ipsen
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this study is to collect some parameters which may help to provide guidance on how Androgen Deprivation Therapy (ADT) drugs are renewed and physician satisfaction.
Eligibility Criteria
Inclusion
- Adult men, ≥18 years old, with recently diagnosed locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy as monotherapy or as concomitant and adjuvant therapy in association with radiation therapy, with a 1 or 3 month GnRH analogue triptorelin formulation
- Expected survival \> 12 months.
- Patients having provided written informed consent.
- Patients mentally fit for completing a questionnaire.
Exclusion
- Treatment with any investigational drug within the last 3 months before study entry or planning to participate in a study.
- Patients who already have been treated with a GnRH analogue within the last year.
- Patients with hypersensitivity to GnRH, GnRH analogue, triptorelin or its excipients.
- Patients with a contraindication according to SmPC.
Key Trial Info
Start Date :
November 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 6 2019
Estimated Enrollment :
368 Patients enrolled
Trial Details
Trial ID
NCT02238366
Start Date
November 1 2013
End Date
June 6 2019
Last Update
July 25 2019
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Arad, Romania
2
Bucharest, Romania
3
Cluj-Napoca, Romania
4
Constanța, Romania